Research Topic: neuroplasticity

Psychedelics action and schizophrenia

This review examines how psychedelic drugs like psilocybin and LSD affect the brain, particularly through serotonin receptors. While these compounds can produce psychosis-like symptoms similar to schizophrenia, they also promote brain plasticity and growth of neural connections. The article discusses whether psychedelics could potentially treat negative symptoms and cognitive problems in schizophrenia patients, despite their mind-altering properties, possibly through lower doses or non-hallucinogenic alternatives.

Read More »

The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects

This review examines how psilocybin may help treat depression by increasing empathy and prosocial behavior. While psilocybin leaves the body within hours, its antidepressant effects can last months, and researchers believe empathy and helping others may explain this lasting benefit. The authors suggest psilocybin starts a positive cycle where increased empathy leads to helping others, which boosts mood and well-being, which further reinforces empathetic behavior.

Read More »

Study protocol for ‘Psilocybin in patients with fibromyalgia: brain biomarkers of action’

Researchers are testing whether psilocybin (the active compound in magic mushrooms) combined with therapeutic support can help people with fibromyalgia, a chronic pain condition. The study will measure brain activity using EEG and brain imaging to understand how psilocybin might reduce pain and improve mental health. Twenty patients will receive guided psilocybin sessions over eight weeks while researchers track changes in brain function and pain levels.

Read More »

Investigating the Potential of Psilocybin for Compulsive Eating in a Rat Model of Binge Eating

Researchers tested whether psilocybin, a psychedelic compound from magic mushrooms, could help reduce compulsive eating in rats bred to binge eat high-fat, high-sugar foods. Using a fear-conditioning experiment, they found that a single dose of psilocybin did not reduce the rats’ compulsive eating behavior at the dosage tested. However, the treatment may have affected fear-related freezing responses, suggesting psilocybin might influence brain circuits involved in learning and memory.

Read More »

New and emerging pharmacologic treatments for MDD

Major depressive disorder affects millions worldwide and current antidepressants often don’t work well or take weeks to be effective. Researchers have developed exciting new treatments that work through different brain mechanisms and show promise for rapid symptom relief. These include nasal spray ketamine (approved 2019), oral medications like zuranolone (approved 2023), and investigational treatments including psilocybin, which show benefits especially for treatment-resistant cases. While many show great promise, more research is needed on long-term safety and how to make them widely available.

Read More »

The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review

This review examines how psilocybin, a compound found in certain mushrooms, may help people recover from traumatic brain injuries. The research suggests that psilocybin could reduce harmful inflammation in the brain, help the brain form new connections to compensate for damage, and improve mood and depression commonly experienced after brain injuries. While promising, the authors emphasize that more clinical trials are needed to confirm safety and effectiveness before psilocybin can be used to treat brain injury patients.

Read More »

Psilocybin as Transformative Fast-Acting Antidepressant: Pharmacological Properties and Molecular Mechanisms

Psilocybin, a compound from certain mushrooms, is being studied as a potential rapid-acting treatment for severe depression that doesn’t respond to standard antidepressants. Unlike conventional antidepressants that take weeks to work, psilocybin shows promise for producing mood improvements within days. The drug works by activating serotonin receptors in the brain and promoting the growth of new neural connections, though researchers are still working to fully understand how it achieves its antidepressant effects.

Read More »

Chronic pain as an emergent property of a complex system and the potential roles of psychedelic therapies

Chronic pain affects millions of people and is often resistant to current treatments. This paper suggests that chronic pain emerges from interconnected biological, psychological, and social factors working together as a complex system. The authors propose that psychedelic-assisted therapies could help by breaking rigid thought and behavior patterns that maintain pain, allowing the brain and mind to reorganize in healthier ways, similar to how mindfulness meditation works but potentially more dramatically.

Read More »

PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity

This study is investigating whether psilocybin (an active compound in magic mushrooms) can help people with obsessive-compulsive disorder (OCD) by improving their mental flexibility and brain plasticity. Participants will receive two doses of psilocybin—a low test dose and a slightly higher therapeutic dose—four weeks apart, while receiving professional psychological support. Researchers will measure changes in cognitive abilities and brain activity to understand how psilocybin might help reduce OCD symptoms like intrusive thoughts and repetitive behaviors.

Read More »

Neonatal Tactile Stimulation Downregulates Dendritic Spines in Layer V Pyramidal Neurons of the WAG/Rij Rat Somatosensory Cortex

Researchers found that gently brushing young rats with epilepsy-prone genetics helps prevent abnormal brain development. Specifically, this tactile stimulation reduces the excessive spiny connections on brain cells in the sensory cortex that are associated with seizures. The study shows that simple, early physical stimulation can have lasting protective effects on brain structure in epilepsy-prone individuals.

Read More »
Scroll to Top